Scientists learn why even treated genital herpes sores boost the risk of HIV infection

...gnificant proportion of these CD4+ T cells carried ccr5 or CXCR4, the cell-surface proteins that HIV uses ...r cells. The percentage of CD4+ T cells expressing ccr5 during acute HSV-2 infection and after healing of ...om unaffected control skin. Moreover, the level of ccr5 expression in CD4+ T cells at the sites of healed ...

Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013

...iretroviral agents -- the integrase inhibitors and ccr5 antagonists -- have been received with different l...n contrast, Pfizer's Selzentry, the first-in-class ccr5 antagonist, has experienced significant obstacles ...t required for its prescription. The landscape for ccr5 antagonists is expected to improve, however, once ...

Sangamo BioSciences Reports First Quarter 2009 Financial Results

...nt's own) CD4+ T cells genetically modified at the ccr5 gene by CCR5-specific zinc finger DNA-binding prot...R5-modified T-cells, suggesting resistance to HIV. ccr5 is a co-receptor that enables HIV to enter and inf.... Individuals carrying a natural mutation of their ccr5 gene, CCR5-delta32, are highly resistant to infect...

GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company

...enhancer I Rescriptor NNRTI (US only) GSK706769 ccr5 antagonist I Retrovir/AZT NRTI Selzentry/Celsentri ccr5 antagonist Trizivir NRTI Viracept Protease ...

Specialists are Highly Satisfied with the Safety and Efficacy of Atripla and Isentress in the Treatment of HIV Patients

... A ccr5 Antagonist That is Dosed Once Daily Could Earn an ...lopers in Integrase Inhibitors and Next Generation ccr5 Antagonists finds that a novel drug in the ccr5 antagonist class that is dosed once daily and achi...

Monogram Announces 2008 Second Quarter Financial Results

...atients to be treated with Selzentry(TM), Pfizer's ccr5 antagonist, and by revenue from use of Monogram's ...ERmark assays, the outlook for Selzentry, Pfizer's ccr5 antagonist HIV drug, reimbursement for Trofile and... and success or failure of any clinical trials for ccr5 inhibitors, entry inhibitors or integrase inhibito...

Study provides clues to preventing and treating cancer spread

...wanted to figure out why "knockout mice" that are missing the cell receptor ccr5 get fewer cancer metastases than normal mice. ccr5 helps control the migration of cells through the body. He injected these k...

Zinc finger proteins put personalized HIV therapy within reach

...gineered T cells. "By inducing mutations in the ccr5 gene using zinc finger proteins, we've reduced the expression of ccr5 surface proteins on T cells, which is necessary fo...ls because it now has an introduced error into the ccr5 gene." Some people are born with a mutation on ...

Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies

...ent is infected with a strain of HIV that uses the ccr5 co-receptor, the CXCR4 co-receptor, or a combinati... patients in all phase II and phase III studies of ccr5 antagonists to date. Together these assays provide...e a molecular diagnostic for patient selection for ccr5 antagonists or other HIV drugs; the risk that phys...

Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay

...Selzentry(TM) (maraviroc), Pfizer's first in class ccr5 antagonist, in August 2007. Optimization of Monogr...say is selecting the most appropriate patients for ccr5 antagonist therapy. Tropism refers to the chemok... HIV uses to enter the cell. "R5" variants use the ccr5 co-receptor, "X4" viruses use the CXCR4 co-recepto...

CCR5 in Medical Technology

DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM ) today announced that guidelines issued by the Department of Health and Human Services (DHHS) recommend that a co-receptor tropism test, such as Monogram's Trofile(TM) assay, should be perf...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

...linical study with vicriviroc, its investigational ccr5 antagonist, for use in first-line therapy of adult...cells by blocking its predominant entry route, the ccr5 co-receptor. Approximately 80-90 percent of treatment-naive patients have virus that uses the ccr5 co-receptor.(1) "CCR5 antagonists, such...

Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives

...utic program for the treatment of HIV/AIDS in high-impact journal Nature Biotechnology demonstrating highly efficient and specific ZFN-modification of ccr5 in human T-cells resulting in an increase in CD4 T-cell counts and a reduction in viral load in an animal model of HIV infection (Perez et al., 2008, ...

Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay

...infected with a strain of HIV that uses either the ccr5 coreceptor, the CXCR4 coreceptor, or a combination... the virus. The production of luciferase in either ccr5 cells, CXCR4 cells or both cell types defines the ... patients in all phase II and phase III studies of ccr5 antagonists to date. In June 2008, optimization ...

Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients

...lysis showing that vicriviroc, its investigational ccr5 receptor antagonist, demonstrated sustained viral ...ting the immune system's CD4 cells by blocking the ccr5 co-receptor. Approximately 50-60 percent of treatm... treatment-naive patients have virus that uses the ccr5 co-receptor.(5) The study evaluates vicriviroc 30 ...

Tobira Therapeutics Inc. Receives US Patent for TBR-652

...rowing portfolio of medicines to treat infectious diseases. In addition, they were recently issued European Patent No. 1,220,842 for TBR-220, a second ccr5 antagonist for the treatment of HIV/AIDS and have an additional patent pending. In response to this news, James Sapirstein, Chief Executive Officer of...

Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells

...which results in the permanent modification of the ccr5 gene encoding an important receptor for HIV infect...individuals that carry a natural mutation in their ccr5 gene suggest that permanent 'knock-out' of the of ccr5 gene is important and clinically relevant for long...

Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients

...linical study with vicriviroc, its investigational ccr5 antagonist, for use in first-line therapy of adult...cells by blocking its predominant entry route, the ccr5 co-receptor. Approximately 80-90 percent of treatm... on this product. 4 Vicriviroc, a next generation ccr5 antagonist, exhibits potent, sustained suppress...

Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials

...development program of PRO 140, an investigational ccr5 monoclonal antibody being studied for the treatmen...itor HIV infected individuals whose virus uses the ccr5 receptor as a portal of entry to healthy cells. Pr...ceptor, the CXCR4 co-receptor, or a combination of ccr5 and CXCR4 to enter cells. Trofile is the only clin...

Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of 'Knock-Out' Cell Lines

...nocking out genes in multiple crop plants and to develop ZFP Therapeutics(TM). We are developing potential treatments for HIV/AIDS by knocking-out the ccr5 gene in T-cells and for brain cancer (glioblastoma) by disrupting the glucocorticoid receptor (GR) in engineered killer T-cells. We expect to file Inv...

CCR5 in Biological News

UC Davis researchers exploring gene therapy to fight AIDS

...ance into the cell by binding to a receptor called ccr5 on the cell's surface. Later in the infection it t... 1 percent of Caucasians that results in a lack of ccr5 receptors on any of their cells. "We also found...reating a gene that would knock down expression of ccr5 and other key receptors and interfere with other r...

Landmark discovery of a Kaposi's sarcoma-associated herpesvirus receptor

...gain entry into cells of the immune system. This discovery quickly led to the identification by Dr. Berger's group and several other research teams of ccr5 as the other HIV coreceptor. By applying the same technology used to identify CXCR4, Drs. Kaleeba and Berger ultimately identified the protein xCT...

Genetic mutation linked to West Nile virus infection

...eoretical basis for the development of therapeutic ccr5 inhibitors, several of which are now in clinical trials, for the treatment of patients with HIV. ccr5 seemed like an ideal drug target, as people missin...ion. But new evidence suggests that the lack of ccr5 is not completely innocuous. Philip Murphy and hi...

Sangamo BioSciences demonstrates its ZFP treatment protects cells from HIV infection

...eases (ZFNTM) designed to specifically disrupt the ccr5 gene. In its anti-HIV preclinical research progr... has designed ZFNs that can be used to disrupt the ccr5 gene, a receptor required for HIV entry into immun...when challenged with the virus. Furthermore, when ccr5 expression was experimentally restored in the ZFN-...

First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes

...was incorrect and the plagues of Europe (1347-1660) were in fact a continuing series of epidemics of a lethal, viral, haemorrhagic fever that used the ccr5 as an entry port into the immune system. Using computer modeling, they demonstrated how this disease provided the selection pressure that forced up th...

Biologists discover why 10% of Europeans are safe from HIV

...was incorrect and the plagues of Europe (1347-1660) were in fact a continuing series of epidemics of a lethal, viral, haemorrhagic fever that used the ccr5 as an entry port into the immune system. Using computer modeling, they demonstrated how this disease provided the selection pressure that forced up th...

CCR5 in Biological Technology

Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM ) today announced that data related to the enhanced performance of the company's HIV tropism assay were presented in an oral presentation at the 17th International HIV Drug Resistance Works...

Schering-Plough Reports Financial Results for 2009 Second Quarter

...iven once daily for seven days. (Announced July 1) Extended to stage two an ongoing Phase II clinical study with vicriviroc, an investigational ccr5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. (Announced July 15) Merck and...

New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance

...tropism process involving one or both coreceptors, ccr5 or CXCR4, of CD4 cells, which help the immune syst...ight infection. HIV-1 viral particles that use the ccr5 coreceptor to infect the cell are called R5-tropic... recommend tropism testing prior to the start of a ccr5 inhibitor, such as maraviroc (Selzentry TM). Three...

Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research

... proposals in this round. People born with a genetic mutation in their ccr5 gene, a critical receptor for HIV entry, are naturally resistant to HIV inf...inger DNA-binding protein nucleases (ZFN(TM)) that specifically disrupt the ccr5 gene in cells. In preclinical work published with their collaborators at t...

Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results

...recognized system for human disease modeling and in vivo drug discovery. A second publication described the successful ZFN-mediated disruption of the ccr5 gene in human T-cells and the positive effects on HIV resistance and reduction in viral load in an animal model of HIV infection. Sangamo's ...

Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS

...rtunistic infections characteristic of AIDS." ccr5 is a co-receptor that enables HIV to enter and inf...t individuals carrying a natural mutation of their ccr5 gene, CCR5-delta32, were highly resistant to infec...n by HIV. These individuals, lacking a functional ccr5 (approximately 1-2% of the general population), ar...

Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic

...s carrying a naturally occurring mutation of their ccr5 gene, a variant known as CCR5-delta32, have been s...cells by the permanent genetic modification of the ccr5 gene. These ZFN-modified CD4 T-cells expanded stab... infection with R5-tropic HIV (virus that uses the ccr5 co-receptor to enter cells), resulting in enrichme...

Monogram Announces 2008 Third Quarter Financial Results

...in the third quarter of 2007. This growth was driven by revenue from Trofile(TM) for selecting HIV patients to be treated with Selzentry(TM), Pfizer's ccr5 antagonist, and by revenue from use of Monogram's PhenoSense HIV(TM) resistance test and Trofile in a phase III trial by a pharmaceutical company cust...

Monogram Receives NASDAQ Notification

...e growth in 2009 both from Trofile(TM), our patient selection assay for the ccr5 antagonist class of HIV drugs, and from HERmark(TM), our recently launched ...evenues; the size, timing and success or failure of any clinical trials for ccr5 inhibitors, entry inhibitors or integrase inhibitors; the risk that our Ver...

Half of Surveyed Physicians Expect to Replace Between 6 Percent and 15 Percent of Their Sustiva Prescriptions with Isentress

...patients to be a critical deterrent to prescribing ccr5 antagonist drugs. "It is highly likely that all subsequent members of the ccr5 antagonist drug class will necessitate a tropism t...s substantial hurdle to wider uptake, marketers of ccr5 antagonist drugs should actively support the devel...

CCR5 in Biological Products

Rat Anti-CCR5 Monoclonal Antibody, Unconjugated, Clone HEK / 1 / 85a from Abcam

Description:... Rat monoclonal [HEK/1/85a] to ccr5 ( Abpromise for all tested applications). entrezGeneID: 1234 SwissProtID: P51681...
Company:Abcam

CCR5 in Biological Dictionary

Zinc finger

... zinc fingers , scientists have shown that they could reduce the viral ... In this study, the zinc finger protein brings a DNA enzyme to the ccr5 gene to ... A zinc finger consists of two antiparallel β strands, and an α helix. ... The zinc finger protein TFIIIA, a positive trans...

Tropism

...... ... for identifying HIV viral tropism – CCR5, CXCR4, or dual/mixed. ... Tropism & HIV Resources. What is Trofile™ How to Order Trofile™ ccr5 Antagonist & Trofile™ ... Other commonly observed tropisms include galvanotropism or electrotropism, ... The term tropism was formerly appl...